230 related articles for article (PubMed ID: 37095531)
21. A case of TFE3 translocation renal cell carcinoma with rare morphological features and literature review.
Xia T; Long H; Liao D; Wang W; Xiao X
Indian J Pathol Microbiol; 2023; 66(1):135-140. PubMed ID: 36656224
[TBL] [Abstract][Full Text] [Related]
22. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
23. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
24. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
25. RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.
Kato I; Furuya M; Baba M; Kameda Y; Yasuda M; Nishimoto K; Oyama M; Yamasaki T; Ogawa O; Niino H; Nakaigawa N; Yano Y; Sakamoto K; Urata Y; Mikami K; Yamasaki S; Tanaka R; Takagi T; Kondo T; Nagashima Y
Histopathology; 2019 Aug; 75(2):254-265. PubMed ID: 30908700
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas.
Medendorp K; van Groningen JJ; Schepens M; Vreede L; Thijssen J; Schoenmakers EF; van den Hurk WH; Geurts van Kessel A; Kuiper RP
Cytogenet Genome Res; 2007; 118(2-4):157-65. PubMed ID: 18000366
[TBL] [Abstract][Full Text] [Related]
27. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
28. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
29. Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma.
Lang M; Vocke CD; Ricketts CJ; Metwalli AR; Ball MW; Schmidt LS; Linehan WM
Urology; 2021 Mar; 149():89-97. PubMed ID: 33242557
[TBL] [Abstract][Full Text] [Related]
30. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
31. TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
Damayanti NP; Cordova RA; Rupert C; Delle Fontane I; Shen L; Orsi S; Klunk AJ; Linehan WM; Staschke KA; Hollenhorst PC; Heppner DE; Pili R
Cancer Res; 2024 Apr; 84(8):1286-1302. PubMed ID: 38266162
[TBL] [Abstract][Full Text] [Related]
32. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
Hong SB; Oh H; Valera VA; Baba M; Schmidt LS; Linehan WM
PLoS One; 2010 Dec; 5(12):e15793. PubMed ID: 21209915
[TBL] [Abstract][Full Text] [Related]
34. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Argani P; Hicks J; De Marzo AM; Albadine R; Illei PB; Ladanyi M; Reuter VE; Netto GJ
Am J Surg Pathol; 2010 Sep; 34(9):1295-303. PubMed ID: 20679884
[TBL] [Abstract][Full Text] [Related]
35. A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.
Kuentz MA; Blons H; Gimenez-Roqueplo AP; Just PA; Laurent-Puig P; Mejean A; Oudard S; Verkarre V
Genes Chromosomes Cancer; 2023 Jun; 62(6):361-366. PubMed ID: 36695651
[TBL] [Abstract][Full Text] [Related]
36. mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma.
Lee HJ; Shin DH; Song JS; Park JY; Kim SY; Hwang CS; Na JY; Lee JH; Kim JY; Park SW; Sol MY
Am J Pathol; 2021 Nov; 191(11):1999-2008. PubMed ID: 34358517
[TBL] [Abstract][Full Text] [Related]
37. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Prakasam G; Mishra A; Christie A; Miyata J; Carrillo D; Tcheuyap VT; Ye H; Do QN; Wang Y; Reig Torras O; Butti R; Zhong H; Gagan J; Jones KB; Carroll TJ; Modrusan Z; Durinck S; Requena-Komuro MC; Williams NS; Pedrosa I; Wang T; Rakheja D; Kapur P; Brugarolas J
J Clin Invest; 2024 Feb; 134(7):. PubMed ID: 38386415
[TBL] [Abstract][Full Text] [Related]
38. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family.
Ramphal R; Pappo A; Zielenska M; Grant R; Ngan BY
Am J Clin Pathol; 2006 Sep; 126(3):349-64. PubMed ID: 16880148
[TBL] [Abstract][Full Text] [Related]
39. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
40. Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate.
Funasaki S; Mehanna S; Ma W; Nishizawa H; Kamikubo Y; Sugiyama H; Ikeda S; Motoshima T; Hasumi H; Linehan WM; Schmidt LS; Ricketts C; Suda T; Oike Y; Kamba T; Baba M
Cancer Sci; 2022 Jul; 113(7):2352-2367. PubMed ID: 35396773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
